mdh.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Clinical experience with Latanoprost: a retrospective study of 153 patients
Mälardalen University, School of Health, Care and Social Welfare. Karolinska Institutet, Stockholm, Sweden.ORCID iD: 0000-0002-5976-5193
1999 (English)In: Acta Ophthalmologica Scandinavica, ISSN 1395-3907, E-ISSN 1600-0420, Vol. 77, no 3, 336-339 p.Article in journal (Refereed) Published
Abstract [en]

Purpose: To evaluate the pressure-reducing effect of latanoprost in a clinical setting. Patients and methods: Data from 153 consecutive patients with open angle glaucoma receiving latanoprost were recorded at baseline (=153), 2 weeks (n=151) and 8 to 12 months (n=89) after starting latanoprost treatment, In 82 patients (54%) latanoprost was added to ongoing treatment, Two patients terminated treatment because of side effects before the first follow-up examination, Results: 56% (84/151) of the patients showed an intraocular pressure reduction of 20% or more after 2 weeks, regardless of baseline therapy. The difference between intraocular pressure before (24.4+/-5.8 mm Hg) and after 2 weeks of latanoprost treatment (19.9+/-6.9 mm Hg) in the total group (n=151) was highly significant (p<0.0001). The pressure reduction was significantly correlated,vith the pretreatment intraocular pressure level (r=0.48, p<0.0001). In the 89 patients who could be followed for 8 to 12 months no significant upward drift in mean intraocular pressure was observed, but in fourteen patients intraocular pressure increased with 5 mm Hg or more. Thirteen patients reported side effects, five of these discontinued the treatment. Conclusion: Latanoprost is obviously an efficient pressure reducing drug which can be used in glaucoma patients as an adjunct to any ongoing therapy with the expectation of clinically relevant intraocular pressure reduction in 45-71% of the patients.

Place, publisher, year, edition, pages
1999. Vol. 77, no 3, 336-339 p.
National Category
Ophthalmology
Identifiers
URN: urn:nbn:se:mdh:diva-12047DOI: 10.1034/j.1600-0420.1999.770318.xISI: 000080866000018Scopus ID: 2-s2.0-0032972193OAI: oai:DiVA.org:mdh-12047DiVA: diva2:407530
Available from: 2011-03-30 Created: 2011-03-30 Last updated: 2016-05-11Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textScopus

Search in DiVA

By author/editor
Martin, Lene
By organisation
School of Health, Care and Social Welfare
In the same journal
Acta Ophthalmologica Scandinavica
Ophthalmology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 110 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf